Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tuvonralimab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06751277
What this trial is testing

QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer

Who this might be right for
Recurrent or Metastatic Endometrial Cancer
xiang yang 26
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07200947
What this trial is testing

A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer.

Who this might be right for
SMARCA4-Deficient TumorLocally Advanced or Metastatic Non-Small Cell Lung Cancer
Zhijie Wang 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07150377
What this trial is testing

A Phase II Single-Arm Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Lenvatinib and TACE for Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma (HCC)
The Second Affiliated Hospital of Shandong First Medical University 41
Testing effectiveness (Phase 2)Looking for participantsNCT07026422
What this trial is testing

Iparomlimab/Tuvonralimab Integrating With Total Neoadjuvant Therapy for pMMR/MSS Locally Advanced Rectal Cancer (IT-TNT)

Who this might be right for
Rectal Malignant Neoplasms
Shandong Cancer Hospital and Institute 54
Testing effectiveness (Phase 2)Active Not RecruitingNCT07776639
What this trial is testing

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction

Who this might be right for
Gastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
Yongxu Jia 34
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07277972
What this trial is testing

Iparomlimab and Tuvonralimab Injection in Combination With Lenvatinib or Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma That Has Failed First-Line Systemic Therapy

Who this might be right for
RCC, Renal Cell Cancer
Tianjin Medical University Cancer Institute and Hospital 36
Post-approval studies (Phase 4)Not Yet RecruitingNCT07004335
What this trial is testing

Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study

Who this might be right for
PD-(L)1CTLA-4Advanced Melanoma+3 more
Hebei Medical University Fourth Hospital 40
Not applicableNot Yet RecruitingNCT07538193
What this trial is testing

Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung (NSCLC)Neoplasm StagingLymphatic Metastasis
Tang-Du Hospital 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07416058
What this trial is testing

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Who this might be right for
Lung Adenocarcinoma
Guangdong Association of Clinical Trials 61
Not applicableNot Yet RecruitingNCT07652983
What this trial is testing

TTE Study of QL1706 in Recurrent/Metastatic Cervical Cancer

Who this might be right for
Recurrent or Metastatic Cervical Cancer
Qilu Hospital of Shandong University 280
Testing effectiveness (Phase 2)Looking for participantsNCT06930118
What this trial is testing

The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.

Who this might be right for
Advanced Colorectal Cancer in the Third-line Treatment and BeyondpMMR/MSS Advanced Colorectal Cancer
Shanghai Changzheng Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT07447570
What this trial is testing

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Who this might be right for
Head and Neck CancerRadiotherapyAnti-PD-1/CTLA-4 Antibody
Second Affiliated Hospital, Zhejiang University, School of Medicine 27
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07035808
What this trial is testing

A Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .

Who this might be right for
Cervical Cancer Stage IVACervical Cancer Metastatic
Zhejiang Cancer Hospital 46
Testing effectiveness (Phase 2)Looking for participantsNCT07291401
What this trial is testing

Radiotherapy Plus CAPOX, and Iparomlimab and Tuvonralimab (QL1706) as Neoadjuvant Therapy for LARC

Who this might be right for
Rectal Cancer Patients
Zhongnan Hospital 108
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07197697
What this trial is testing

A Phase II Exploratory Study of Iparomlimab and Tuvonralimab Combined With Chemotherapy in Neoadjuvant Treatment of HR+/HER2- Breast Cancer Patients

Who this might be right for
Breast Cancer
Anhui Provincial Cancer Hospital 30
Large-scale testing (Phase 3)Enrolling By InvitationNCT06910072
What this trial is testing

Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer（UPGRADE-TNBC）

Who this might be right for
Triple-Negative Breast Cancer (TNBC)Neoadjuvant Therapy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 32
Testing effectiveness (Phase 2)Looking for participantsNCT06941766
What this trial is testing

Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Who this might be right for
Intermediate Trophoblastic Tumor
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06897046
What this trial is testing

Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)II-IIIB
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 90
Testing effectiveness (Phase 2)Looking for participantsNCT07150247
What this trial is testing

Safety and Efficacy of IB-FOLFIRI in BRAF V600E-Mutant Metastatic Colorectal Cancer

Who this might be right for
BRAF V600 Colorectal Cancer
Sun Yat-sen University 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07549906
What this trial is testing

Neoadjuvant Iparomlimab/Tuvonralimab Plus CAPEOX Versus Iparomlimab/Tuvonralimab Plus CAPEOX and Propranolol for Locally Advanced pMMR Colon Cancer: A Prospective, Single-Center, Multi-Cohort Study

Who this might be right for
Colon Cancer (Stage II &Amp; III)ImmunotherapyBeta Blocker+1 more
Sun Yat-sen University 45
Next Page